Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology
04 oct. 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology
04 sept. 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Announces Initiation of Registrational Trial of Melphalan/HDS in Intrahepatic Cholangiocarcinoma
07 mai 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
ASLAN Pharmaceuticals Sponsors Cholangiocarcinoma Foundation Annual Conference 2018
31 janv. 2018 01h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Jan. 31, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN) (6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
Bile Duct Cancer (Cholangiocarcinoma) Treatment Market to show Incremental Opportunity of US$ 144.2 Mn by 2025 - Persistence Market Research
21 déc. 2017 03h32 HE
|
Persistence Market Research
New York City, NY, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Persistence Market Research(PMR) forecasts the global bile duct cancer treatment market to grow from about US$ 168 Mn in 2017 to about US$ 312 Mn...
ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
30 juin 2016 07h00 HE
|
ArQule, Inc.
75% disease control rate, including a 25% objective response rate, was observed in 12 evaluable patients harboring FGFR2 genetic alterations BURLINGTON, Mass., June 30, 2016 (GLOBE NEWSWIRE) --...
ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
23 juin 2016 07h00 HE
|
ArQule, Inc.
BURLINGTON, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that preliminary data from the ongoing phase 2 portion of a phase 1/2 trial in intrahepatic...
ArQule Reports Fourth Quarter and Full Year 2015 Financial Results
29 févr. 2016 07h00 HE
|
ArQule, Inc.
Conference Call Scheduled Today at 9:00 a.m. ET BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the fourth quarter and...
ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 087
15 déc. 2015 07h30 HE
|
ArQule, Inc.
Orphan drug designation marks significant regulatory milestone for phase 2 trialAdditional response in phase 1b further validates development for ARQ 087 in cancers with FGFR2 genetic alterations ...